A method of diagnosing tuberculosis (TB) is provided. The method comprising the step of testing a biological sample from the subject for the presence of CC4 and at least one other biomarker selected from the group consisting of CC4b, procalcitonin, CCL1, apolipoprotein-CIII, RANTES and TNF-. A device, kit and computer-implemented method for diagnosing (and optionally also treating) TB are also provided.

The present invention relates to methods for the prediction of the progression of chronic kidney disease in a patient. More particularly, the invention relates to the early prediction of the fast progression of chronic kidney disease using specific biomarker signatures in urine sample of patients.

Biomarkers are provided that are predictive of a subject's responsiveness to a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.

The present invention relates to a method of diagnosing over active bladder disorder (OAB), the method comprising: measuring the concentrations of adenosine triphosphate (ATP), acetylcholine (ACh), nitrite, monocyte chemoattractant protein 1 (MCP-1) and interleukin 5 (IL-5) in a sample obtained from a subject; normalising the concentrations to the concentration of creatinine (Cr) in the sample; range standardising the normalised concentrations and subject's age to the following values: Age to 120 years old; ATP/Cr to 0.000001 mole/mgdl.sup.1; ACh/Cr to 0.1 mole/mgdl.sup.1; Nitrite to 200 nM/mgdl.sup.1; MCP-1/Cr to 100 pgml.sup.1/mgdl.sup.1; IL-5/Cr 100 pgml-mgdl.sup.1; applying the normalised and range standardised concentrations to the following formula: Logit (p)=1.7381.4044.9852.914subject's age+3315.9595435.254[ATP]/[Cr]+(25204.19420268.337)[ACh]/[Cr]+26.79932.967[nitrite]/[Cr]+6.75525.132 [MCP-1]/[Cr]+(61.838148.740) [IL-5]/[Cr] and calculating Logit; wherein a Logit value above a predetermined threshold indicates that the subject has OAB. Methods for monitoring the progression of OAB using the method, kits for use in the method and computer systems and programs configured to execute the method are also provided.

The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and/or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.

Methods and kits for characterizing liver damage in an individual are provided. The methods employ the use of immune analytes as biomarkers for detecting liver damage and predicting the likelihood that an individual suffering from liver damage will experience life-threatening liver failure. Concentration values for serum albumin and other identified immune analytes are obtained or determined from a blood sample taken from the individual. The obtained concentration values are then compared to corresponding concentrations from individuals having a healthy liver. By comparing the concentrations, an individual's likelihood of developing life-threatening liver failure and needing a liver transplant within a given time period (e.g., 6 months) can be identified.

Disclosed is a method of diagnosing graft-versus-host disease, comprising measuring the level of CCL8 protein in a sample obtained from a subject as an indicator for the diagnosis or course of graft-versus-host disease. Also a diagnostic reagent for graft-versus-host disease comprising an anti-CCL8 antibody is disclosed. The method of the present invention enables diagnosis of the onset of graft-versus-host disease and monitoring of the progress, in particular, differential diagnosis between graft-versus-host disease and an infectious disease. The present invention also provides a method for treating graft-versus-host disease utilizing the anti-CCL8 antibody.

A method for predicting, diagnosing and prognosticating a neurodegenerative disease, such as Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and neurodegeneration in Down's syndrome (NDS) using glutaminyl cyclase (QC) as a diagnostic/prognostic indicator. The use of antibodies binding to QC and kits for performing said diagnostic method are also provided.

Provided herein are methods for predicting the clinical sensitivity of an inflammatory disease (e.g., ankylosing spondylitis) and a subject's response to treatment with apremilast using the level of a biomarker (e.g., MCP1). Also provided herein are methods for treating an inflammatory disease.

A method for treating muscular dystrophy is described, including extracorporeally treating a patient's bodily fluid. The bodily fluid is removed from a patient before treatment and returned to the patient after treatment. The treatment targets an antigen associated with muscular dystrophy, such as interleukin-17 (IL-17), TNF- (tumor necrosis factor-alpha), interleukin-6 (IL-6), CTGF- (transforming growth factor-beta), MCP-1 (monocyte chemotactic protein-1), and combinations thereof. The treatment removes the antigen from the bodily fluid. Preferably, the treatment is removed from the bodily fluid before returning to the patient.